Department of Pharmacy Practice and Science

Liver Disease

Associate Professor Kenneth Bauer’s, PharmD, PhD, research includes pre-clinical to clinical pharmacology, as well as design and analysis of phase I-III clinical trials for companies in the pharmaceutical industry through the Clinical Pharmacology Unit.  Research now underway includes animal pharmacology and pharmacokinetics in product development related to Dr. MacVittie’s NIH study into medical countermeasures against radiation and other threats.  Research also includes the investigation of an oral anti-inflammatory treatment for cancer radiation patients with Dr. Gordon in the Dental School; and the pharmacology of pegylated GM-CSF after bone marrow stem cell transplant in pre-clinical studies.

Bauer’s recent work includes an assessment of the relationship between treatment with the anti-angiogenesis/matrix metalloproteinase inhibitor Col-3 and the circulating matrix metalloproteinase (MMP) MMP-2 and MMP-9 concentrations with patient response. His work extends into the department’s 2,500 foot laboratories which are equipped for pharmacokinetic analyses in human specimens and animal studies.

Our recent publications include:

Coowanitwong I, Keay SK, Natarajan K, Garimella TS, Mason CW, Grkovic D, Bauer KS.  Toxicokinetic Study of Recombinant Human Heparin-Binding Epidermal Growth Factor-Like Growth Factor (rhHB-EGF) in Female Sprague Dawley Rats.  Pharmaceutical Research.  In press 2007.

Edelman MJ, Bauer K, Wu S, Smith R, Bisacia S, Dancey J. Phase I and pharmokinetic study of UCN-01 and carboplatin in advanced solid tumors. Clin Cancer Res 2007:13(9):2667-74.

Coowanitwong I, Keav SK, Natarajan K, Garimella TS, Mason CW, Grkovic D, Bauer KS. Toxicokinetic study of recombinant human heparin-binding epidermic growth factor-like growth factor (rhhb-EGF) in female Sprague Dawley rats. Pharm Res 2007 Aug 1; epub ahead of print.